Breaking
Medicus Pharma Ltd. to Present at Biotech Showcase 2026, Advancing SkinJect ProgramEli Lilly's Legal Victory Over Noom's GLP-1 ClaimsBBSW AI Solution Event: Daily Roundup
🇺🇸 FDA

Povetacicept News

🇺🇸 Americas ← All news

FDA Povetacicept coverage for business development, investment, and market access teams

Latest on Povetacicept

Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
NewsIgA NephropathyJun 5, 2026

Vertex Announces FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy

Vertex Pharmaceuticals announced that the FDA has accepted its Biologics License Application for accelerated approval of povetacicept in IgA nephropathy, with a PDUFA target date of November 30, 2026. The filing is supported by positive week 36 interim analysis data.

Dr. Sarah Mitchell

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.